Effect of Teriparatide on Unstable Pertrochanteric Fractures
Table 5
Clinical outcome measures of patients in the control and teriparatide groups at last follow-up.
Three months postoperatively
Six months postoperatively
12 months postoperatively
Last follow-up
Mobility
Group A
Group B
Group A
Group B
Group A
Group B
Group A
Group B
= 44
= 29
= 44
= 29
= 44
= 29
= 44
= 29
Able to get about the house (0–3)
1.4 ± 0.5
1.8 ± 0.4*
2.2 ± 0.4
2.8 ± 0.4*
2.8 ± 0.4
2.9 ± 0.2
2.9 ± 0.3
2.9 ± 0.1
Able to get out of the house (0–3)
0.9 ± 0.3
1.3 ± 0.5*
1.6 ± 0.5
2.0 ± 0.2*
2.1 ± 0.3
2.1 ± 0.3
2.2 ± 0.4
2.3 ± 0.5
Able to go shopping (0–3)
0
1.0 ± 0.4*
0.9 ± 0.3
1.4 ± 0.5*
1.5 ± 0.5
1.6 ± 0.5
1.6 ± 0.5
1.8 ± 0.5
Total mobility score (0–9)
2.3 ± 0.7
4.1 ± 0.9*
4.7 ± 0.8
6.1 ± 0.8*
6.4 ± 1.0
6.8 ± 0.8
6.8 ± 1.0
7.1 ± 0.9
Pain score (1–4)
2.5 ± 0.6
2.1 ± 0.7*
1.8 ± 0.6
1.5 ± 0.5*
1.5 ± 0.5
1.3 ± 0.5
1.2 ± 0.5
1.1 ± 0.4
Group A: patient without any supplementation of pharmacologic treatment. Group B: patient treated with teriparatide. Values are shown as mean ± standard deviation. values for between-group comparisons were determined by Student’s -test which was used for parametric variables. *Statistically significant ( value < 0.05).
